➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

TECENTRIQ Drug Profile

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: TECENTRIQ

Patents:	41
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for TECENTRIQ

Recent Clinical Trials for TECENTRIQ

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Elizabeth Buchbinder	Phase 2
Pfizer	Phase 2
Ulrik Lassen	Phase 2

See all TECENTRIQ clinical trials

Pharmacology for TECENTRIQ

Ingredient-type	Antibodies, Monoclonal, Humanized Antibodies, Monoclonal Antibodies
Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions

Patent Text Search: US Patents for TECENTRIQ

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)	2035-06-26	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	ModernaTX, Inc. (Cambridge, MA)	2035-12-23	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	ModernaTX, Inc. (Cambridge, MA)	2036-05-18	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	Immunomedics, Inc. (Morris Plains, NJ)	2035-06-25	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	ChemoCentryx, Inc. (Mountain View, CA)	2036-06-13	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	SNIPR TECHNOLOGIES LIMITED (London, GB)	2036-06-05	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for TECENTRIQ

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2018217227	Start Trial
Turkey	201901824	Start Trial
China	109715172	Start Trial
India	1331DEN2012	Start Trial
European Patent Office	2462988	Start Trial
Japan	2013503200	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Dow

McKesson

Johnson and Johnson

Moodys

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.